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Under the Direction of Charlie Garnett-Benson, PhD

ABSTRACT
Radiotherapy remains effective at treating primary, early-stage tumors, however it
produces nominal results in late-stage and metastatic tumors. This has led to a shift towards more
targeted immune-based therapies. Yet the use of most approved cancer immunotherapies is
limited to only a few cancer types and in the absence of effective anti-tumor immunity tumors
can successfully evade immune surveillance. Tumors employ multiple mechanisms for avoiding
immune elimination including down-regulation of positive signals to tumor specific CD8+
cytotoxic T cells (CTLs) and the accumulation of CD4+ regulatory T (TREG) cells which can
suppress the anti-tumor activity of effector CTLs. Radiation has been reported to enhance antitumor immunity through such mechanisms as tumor cell death or phenotypic modulation of
tumor cells, however the impact of radiotherapy on TREG cells is less clear.

The goal of this dissertation was to investigate the direct effect of radiation on the
phenotypic characteristics and functional activity of induced TREG cells and to examine the
indirect effect of radiation on TREG frequency. We found that exposure to sub-lethal radiation
decreased the expression of Foxp3 in TREG cells and differentially modulated the expression of
several TREG signature molecules. This loss of Foxp3 and modulation of several TREG associated
molecules resulted in a reduction of suppressive activity. Radiation has previously been shown to
modulate the expression of genes in tumor cells that can impact T cell activity such as OX40L
and 4-1BBL. Thus, a secondary goal of the research was to assess the effect of radiation-induced
expression of tumoral OX40L and 4-1BBL on TREG number in two commonly used tumor
models, 4T1 and MC38. Additionally, we examined 4T1 and MC38 tumors for changes in
immune cell composition post-treatment. We found that radiation differentially modulated
OX40L and 4-1BBL expression in our tumor models, as well as reduced TREG frequency.
However, induced expression of OX40L did not correlate with the observed decrease in TREG
frequency. Further, we found that radiotherapy differentially modulated the immune cell profile
of 4T1 and MC38 tumors. These findings could support the design for rationale combinations of
cancer immunotherapies with radiation treatment.

INDEX WORDS: TREG, Radiation therapy, Co-stimulatory molecules, Cancer immunotherapy,
Breast cancer, Colorectal cancer
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INTRODUCTION

Immense research has been done to combat the increasing incidence of cancer diagnoses,
however it remains a public health concern. Ranking 2nd in disease-related deaths in the United
States cancer is estimated to cause the death of more than half a million people in 2019
(American Cancer Society 2019). Standard therapies, such as radiation and chemotherapy,
effectively treat primary and early-stage tumors, however metastatic and late-stage tumors offer
few therapeutic options thus shifting the field towards immune-based therapies, which aim to
stimulate a patients’ own immune system to better attack cancer cells.
1.1

Cancer immunoediting
Cancer immunoediting is a novel theory that describes the effect of the immune system

on tumor development. The initial stage of cancer elimination, or cancer immunosurveillance, is
a process by which immune cells eliminate continuously arising transformed cells (Dunn, Old,
and Schreiber 2004). During this stage tumor elimination is reportedly achieved by interferon-g
(IFN-g) production and lymphocyte effector function. The production of endogenous IFN-g was
found to protect mice from transplanted tumor growth and spontaneous tumor formation (Kaplan
et al. 1998; Street et al. 2002). Further, IFN-g was shown to specifically target tumor cells by
enhancing tumor immunogenicity by upregulating components of the MHC class I pathway
(Shankaran et al. 2018). Cellular effectors required for cancer immunosurveillance include
components of both the innate and adaptive immune system. Mice lacking ab T cells and gd T
cells showed an increased incidence of tumor development compared to control mice (Girardi et
al. 2003). Additionally, increased tumor formation was also observed in mice depleted of NK or
NKT cells (Smyth et al. 2000).
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The second stage of cancer immunoediting is equilibrium. This phase describes the
dynamic balance where IFN-g production and lymphocyte effector function relentlessly attack
tumor cells thereby prohibiting tumor growth but are unable to eradicate transformed cells
(Dunn, Old, and Schreiber 2004). As the longest phase, equilibrium allows for the development
of tumor heterogeneity and genetic instability in cells that survive elimination. The final stage of
immunoediting is escape. Tumor cell variants that were selected for during equilibrium are now
able to grow unchecked even in the presence of a competent immune system (Dunn, Old, and
Schreiber 2004).
1.1.1 Immunosuppression and tumor escape
Tumor cells are highly effective at inducing a variety of immunosuppressive mechanisms
to aid in tumor escape. The secretion of immunosuppressive molecules such as transforming
growth factor b1 (TGF-b1) by tumor cells can inhibit T cell responses (Y. Liu and Cao 2016).
Additionally, TGF-b1, along with several chemokines, recruit suppressive cells to the tumor
microenvironment. Suppressive cell types that play a crucial role in tumor escape and
progression include MDSCs, TAMs, and CD4+ regulatory T (TREG) cells (Y. Liu and Cao
2016).
TREG cells are a specialized subset of CD4+ T cells. Naturally derived in the thymus,
TREG cells are characterized by their expression of the high affinity IL-2 receptor, CD25, and the
transcription factor forkhead box P3 (Foxp3) (Shimon Sakaguchi et al. 2008). Important for
immune tolerance and homeostasis, these cells function by suppressing the activity of autoreactive and pro-inflammatory effector T cells (S Sakaguchi et al. 1995; Shimon Sakaguchi et al.
2009; Erdman and Poutahidis 2010). In addition to naturally derived TREGS (nTREGS), TREGS can
be induced (iTREG) in the periphery such as within the tumor microenvironment (Tsai et al.
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2014). Naïve CD4+CD25- T conventional cells can be induced to express a TREG phenotype
following T cell receptor stimulation in the presence of IL-2 and TGF-b1 (Facciabene, Motz, and
Coukos 2012; Povoleri et al. 2013). Though identical in their suppressive function, these cells
differ in their stability of Foxp3 (Zou 2006; Floess et al. 2007). Foxp3 is a master regulator in
TREG cells and is essential for their development and suppressive function (Maruyama et al.
2011). In nTREGS, Foxp3 expression is highly stable and constitutively expressed whereas in
iTREGS, such as those induced at tumor sites, Foxp3 expression is unstable (Povoleri et al. 2013;
Maruyama et al. 2011). This instability is linked to partial CpG demethylation of the Foxp3
promoter (Haiqi, Yong, and Yi 2011).
Unfortunately, in cancerous conditions the suppressive activity of TREGS is intended to
induce and maintain a suppressive tumor microenvironment thereby enabling immune evasion
and unrestricted cell growth (Zou 2006). It is therefore unsurprising that an increase in TREG
frequency has been reported in several cancer types, including colorectal and breast (Watanabe et
al. 2010; Hua et al. 2016; Hanke et al. 2015; Plitas et al. 2016). Though numerous cancer types
exhibit elevated TREG number, the prognostic implications are wholly cancer dependent. While
TREG cell accumulation correlates with a poor prognosis in such cancers as breast, ovarian, lung,
and melanoma the opposite trend has been observed in colorectal and Hodgkin’s lymphoma
where high TREG infiltration correlates with improved patient prognosis indicating the need to
better understand TREG cell biology and its role in tumor progression (Chaudhary and Elkord
2016).
1.2

Radiation and cancer treatment
More than half of cancer patients are treated with radiotherapy. Traditionally, radiation

has been used to directly kill tumor cells. High dose radiotherapy, administered in fractionated
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doses, induces DNA double-strand breaks. This leads to apoptosis and necrosis of tumor cells
mediated by WT p53 (Fei and El-Deiry 2003; J. song Wang, Wang, and Qian 2018). However,
several cancers contain mutated versions of p53 which has been shown to reduce sensitivity of
tumor cells to radiation-induced cell death (Hollstein et al. 1991; J. M. Lee and Bernstein 1993).
Aside from the direct killing of tumor cells, radiation can be used therapeutically to
induce immunogenic cell death (ICD) at single doses of <2 Gy or when given as
hypofractionated doses of >2 Gy to <25 Gy (Kumari et al. 2016). ICD is defined as cell death
that elicits a robust immune response. Two major factors that are needed to produce an effective
immune response are antigenicity and adjuvanticity (Galluzzi et al. 2017). Radiation can induce
antigenicity by increasing the peptide repertoire (Reits et al. 2006). Further, radiation induced
ICD depends on danger signals such as ATP secretion, type I IFN signaling, and UPR-dependent
exposure of CALR which induce adjuvant-like effects. ICD exposes CALR, an ER chaperone,
on the cell membrane which serves as an “eat me” signal promoting phagocytosis and antigen
uptake by antigen presenting cells (Galluzzi et al. 2017). Additionally, the secretion of ATP
serves as a chemotactic agent leading to the recruitment of dendritic cells (DCs). Lastly,
radiation stimulates the secretion of type I IFNs, notably IFN-b, by tumor cells leading to
chemokine secretion and DC recruitment (Galluzzi et al. 2017; Vanpouille-Box et al. 2017).
Overall, ICD of tumor cells induces the release of tumor-specific antigens that leads to enhanced
DC activation and an effective antitumor immune response.
In addition to ICD, radiation has been shown to induce immunogenic modulation (IM), as
reviewed in (Kumari et al. 2016). IM describes the radiation-induced alterations to tumor cell
phenotype that enhances CTL killing (Fig. 1.1). Radiation has been shown to induce the
expression of major histocompatibility complex class I (MHC class I), MICA/B, and multiple
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death receptors (Fas, DR4, DR5) on tumor cells (Reits et al. 2006; J. Y. Kim et al. 2006; Ifeadi
and Garnett-Benson 2012). In addition, radiation induces T cell infiltration by increasing the
expression of vascular cell adhesion molecule (VCAM-1) and chemokines such as CXCL16
(Lugade et al. 2005; Matsumura and Demaria 2010). Thus, these findings highlight the ability of
radiation to alter the phenotype of tumor cells, thereby inducing a more immunogenic
microenvironment.
An intriguing effect of radiation treatment is the abscopal response. A rare event, the
abscopal response is an immune-mediated response to local tumor irradiation that induces a
systemic antitumor immune response (Y. Liu et al. 2018). It is not fully understood how local
tumor irradiation can generate a systemic antitumor immune response though ICD plays an
important role. Radiation monotherapy has resulted in abscopal responses in a number of case
studies, however these results are not easily reproducible (Azami et al. 2018). It is now believed
that combination radiation and immunotherapy treatment can enhance the abscopal effect as
combination therapy has been shown to further enhance the antitumor immune response when
compared to radiation or immunotherapy alone (Dewan et al. 2009; Deng et al. 2014).
While radiation remains a standard method of care for several cancer types, singular use
fails to eradicate some advanced-stage tumors (Jarosz-Biej et al. 2019). Interestingly, research
has demonstrated the effectiveness of radiation as a partner for immune based cancer
immunotherapies (Demaria, Coleman, and Formenti 2017). Radiation has been shown to upregulate the expression of immunomodulatory molecules such as MHC class 1 and Fas death
receptors in various tumor types, proteins capable of inducing an antitumor immune response at
radiation doses £10 Gy (Garnett et al. 2004; Ifeadi and Garnett-Benson 2012). Previous studies
from our lab, and others, have shown an increase in tumor-specific CTL killing following
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exposure to radiation (Kumari and Garnett-Benson 2016; Bernstein et al. 2014). This enhanced
sensitivity to killing was mediated by the radiation-induced expression of the co-stimulatory
molecules OX40L and 4-1BBL on tumor cells, which we found to be epigenetically regulated
(Kumari et al. 2013). Additionally, several studies have demonstrated the importance of CTLs in
effective radiation and immunotherapy treatment in murine tumor models (Deng et al. 2014; K.
J. Kim et al. 2017).

Figure 1.1 Immunogenic modulation of tumor cells by radiation
Generated from “Future Oncology” (Kumari et al. 2016)
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1.2.1 Cancer immunotherapy strategies and ways to overcome resistance
It has been well documented that the effectiveness of cancer immunotherapy is dependent
on its ability to generate antigen specific CTLs capable of killing tumor cells (Tsai et al.
2014)(Ellmark et al. 2017). However, the accumulation of suppressive immune cells (TREGS,
MDSCs, TAMs) and expression of inhibitory molecules (CTLA-4, PD-1, PD-L1) within the
tumor microenvironment inhibits the cytolytic activity of CTLs. The use of immune checkpoint
blocking (ICB) antibodies are intended to block the binding of inhibitory molecules and boost
the antitumor immune response. Currently there are several FDA approved ICB antibodies on the
market against CTLA-4 (Ipilimumab), PD-1 (Pembrolizumab, Nivolumab, and Cemiplimab),
and PD-L1 (Atezolizumab, Avelumab, and Durvalumab).
Despite major advances in immunotherapy, the clinical use of ICB antibodies is limited
to a small number of cancer types (Lee Ventola 2017). Currently, ICB antibodies are approved
for use in several cancer types, including melanoma, non-small cell lung cancer, and bladder
cancer. Treatment with ICB antibodies has been shown to increase patient survival (Hodi et al.
2010; Topalian et al. 2019). However, most eligible patients are non-responsive, while some that
initially responded well to treatment later acquire resistance (Pitt et al. 2016; Koyama et al.
2016).
Acquired resistance to ICB antibodies has revealed the need for additional treatment
approaches. One such method is the development and use of co-stimulatory agonist antibodies.
Several clinical trial studies are currently underway to evaluate the efficacy of OX40 and 4-1BB
agonist antibodies. OX40 and 4-1BB are co-stimulators belonging to the tumor necrosis factor
superfamily that bind to OX40L and 4-1BBL, respectively (Croft 2009). The ligands OX40L
(CD252) and 4-1BBL (CD137L) are typically expressed on antigen presenting cells (APCs) and
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endothelial cells and send positive signals to T cells. Inducibly expressed on activated CD4+ and
CD8+ T cells, OX40 and 4-1BB are involved in the promotion of effector T cell clonal
expansion, survival, and cytokine induction (Croft et al. 2009; Vinay and Kwon 2012).
Conversely, both OX40 and 4-1BB signaling have been shown to inhibit the conversion of naive
CD4+ T cells into TREGS and send negative signals into existing TREGS (Vu et al. 2007; Piconese,
Valzasina, and Colombo 2008; Bulliard et al. 2014; Smith, Hoeizinger, and Dominguez 2011).
These are important signals for promoting tumor immunity. Treatment of tumor-bearing mice
with agonist antibodies to OX40 and 4-1BB have been reported to induce effective anti-tumor
immune responses (Vinay and Kwon 2012; Gough et al. 2008; Curran et al. 2011; Barsoumian,
Yolcu, and Shirwan 2016).
1.3

Current gaps in knowledge

1.3.1 Direct impact of radiation on TREGS
Despite extensive research, the impact of radiation on TREG cells remains controversial.
Several studies have shown that TREGS are more radio-resistant compared to other lymphocyte
populations, however it is unclear what effect it imparts on their functionality (Baba et al. 2012;
Qu, Jin, et al. 2010). Studies by Qu et al. found no difference in the suppressive function of
TREGS from radiation treated mice compared to control mice, though research by Balogh et al.
and Billiard et al. observed decreased functional activity in irradiated TREGS (Qu, Zhang, et al.
2010; Balogh et al. 2013; Billiard et al. 2011). In addition, studies by Muroyama et al. and
Kachikwu et al. reported increased TREG number in locally irradiated tumors compared to
control, in vivo (Muroyama et al. 2017; Kachikwu et al. 2011), while Cao et al. and Liu et al.
observed a decrease in in vitro and whole-body tumor irradiated studies, respectively (Cao et al.
2009; R. Liu et al. 2010). The reason for such discrepancies is unclear. It is possible that the time
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of data acquisition post-radiation may impact the frequency of TREGS observed, as well as
experimental design and tumor model examined. Additionally, the composition of natural versus
induced TREGS within the research model may also play a factor. As such, it is unclear how
radiation directly effects TREG phenotype and suppressive function, thus understanding its role
could lead to a more targeted use of radiation in combination with cancer immunotherapy.
1.3.2 How radiation-induced tumor modulation regulates TREG frequency
Radiation has been shown by our lab, and others, to alter the phenotype of colorectal and
prostate cancer cells by enhancing their expression of the co-stimulatory molecules OX40L and
4-1BBL (Bernstein et al. 2014; Kumari and Garnett-Benson 2016). Tumor-induced expression of
these proteins was found to enhance CTL effector function in a synergistic manner. Interestingly,
signaling through OX40 or 4-1BB was found to abrogate Foxp3 expression and inhibit the
suppressive function of TREG cells (Smith, Hoeizinger, and Dominguez 2011; Vu et al. 2007;
Piconese, Valzasina, and Colombo 2008). Thus, part of this study was to determine whether
radiation-induced modulation of co-stimulatory and co-inhibitory molecules, on tumor cells,
correlates with reduced TREG cell frequency and if phenotypic changes occurring in common
murine models impact the post-radiation tumor microenvironment.
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IONIZING RADIATION MODULATES THE PHENOTYPE AND FUNCTION OF
HUMAN CD4+ INDUCED REGULATORY T CELLS

Samantha S. Beauford, Anita Kumari and Charlie Garnett-Benson
Submitted to BMC Immunology
Under review

2.1

Abstract

Background: The use of immunotherapy strategies for the treatment of advanced cancer is
rapidly increasing. Most immunotherapies rely on induction of CD8+ tumor-specific cytotoxic T
cells that are capable of directly killing cancer cells. Tumors, however, utilize a variety of
mechanisms that can suppress anti-tumor immunity. CD4+ regulatory T cells can directly inhibit
cytotoxic T cell activity and these cells can be recruited, or induced, by cancer cells allowing
them to escape from immune attack. The use of radiation as a treatment for cancer has been
reported to enhance anti-tumor immunity by several mechanisms involving tumor cell death or
phenotypic modulation of tumor cells. Less is known regarding the impact of radiation directly
on suppressive regulatory T cells. In this study we investigate the direct effect of radiation on
human TREG viability, phenotype, and suppressive activity.
Results: Both natural and TGF-b1-induced TREG cells exhibited increased resistance to radiation
(5-10 Gy) as compared to CD4+ conventional T cells. Radiation, however, decreased Foxp3
expression in natural and induced TREG cells though the reduction was more robust in induced
TREGS. Treatment differentially modulated the expression of signature iTREG molecules, inducing
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increased expression of LAG-3 and CD73 and decreased expression of CD25 and CTLA-4.
Irradiated iTREGS exhibited a reduced capacity to suppress the proliferation of CD8+ T cells.
Conclusions: Our data demonstrates that while human TREG cells may be more resistant to
radiation-induced death it can cause downregulation of Foxp3 expression, as well as modulate
the expression of CD25, CTLA-4, LAG-3, and CD73 signature molecules. Lastly, irradiated
TGF-b1-induced TREGS were less effective at inhibiting CD8+ T cell proliferation. These data
suggest that radiotherapy could be utilized to effectively target and reduce TREG activity
particularly when combined with anti-tumor immunotherapies.
2.2

Introduction
Currently, a variety of immunotherapeutic agents are being used to treat advanced

malignancies, most notably CTLA-4 and PD-1/PD-L1 checkpoint blocking antibodies. Efficient
tumor control by immunotherapies relies heavily on CD8+ cytotoxic T lymphocyte (CTL)
activity (Fransen et al. 2013; Redmond, Linch, and Kasiewicz 2014; Deng et al. 2014). While the
most effective immunotherapies generate tumor-specific CTLs, tumors are often able to induce
an immunosuppressive microenvironment thereby evading immune cell killing (A. A. Wu et al.
2015). A major strategy of tumor-induced immunosuppression is through the recruitment and
induction of CD4+ regulatory T (TREG) cells in the tumor microenvironment (Su et al. 2017;
Wiedemann et al. 2016).
TREGS are a suppressive subset of CD4+ T cells important for preventing autoimmunity
(Smigiel et al. 2014). These cells are characterized by expression of the high affinity IL-2
receptor, CD25, and the transcription factor forkhead box p3 (Foxp3) (Hori, Nomura, and
Sakaguchi 2003). TREGS can be naturally derived in the thymus (nTREG), or they can be induced
in the periphery from naïve CD4+ precursors (iTREG) (Su et al. 2017; Valzasina et al. 2006; G.
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Zhou and Levitsky 2007). Several cancer types are known to contain high levels of TREGS that
facilitate escape from immune surveillance (Viguier et al. 2004; Miller et al. 2006; Mizukami et
al. 2008). To maintain an immunosuppressive microenvironment tumor cells have been reported
to recruit peripheral TREGS as well as induce conversion of CD4+CD25- T cells into TREGS within
the tumor (Mizukami et al. 2008; Ward et al. 2015; Kuehnemuth et al. 2018; V. C. Liu et al.
2007; Mittal et al. 2008). Though nTREG and iTREG cells both have suppressive function iTREGS
reportedly have unstable Foxp3 expression due to partial demethylation of CpG motifs within the
foxp3 locus (Floess et al. 2007). Functionally, TREGS are capable of inhibiting the proliferation
and killing activity of CTLs through several mechanisms: [a] secretion of transforming growth
factor-b1(TGF-b1) and IL-10, [b] metabolic disruption through CD39 and CD73 (Deaglio et al.
2007), or [c] contact-dependent inhibition via cytotoxic T lymphocyte-associated antigen 4
(CTLA-4), lymphocyte activation gene 3 (LAG-3), and programmed death ligand 1 (PD-L1)
signaling (Huang et al. 2004; S. P. Wu et al. 2018).
Ionizing radiation remains a common treatment modality for several cancer types and is
often used in combination with immunotherapy based strategies as radiation alone is insufficient
to eradicate tumor burden in advanced disease (Jarosz-Biej et al. 2019). Interestingly, radiation
has been shown to promote and enhance antitumor immune responses. Research in our lab, and
others, has shown that tumor cells exposed to low doses of radiation can increase the expression
of several cell surface receptors on tumor cells including MHC class I, death receptors , and
effector costimulatory molecules such as OX40L and 4-1BBL (Garnett et al. 2004; Ifeadi and
Garnett-Benson 2012; Kumari and Garnett-Benson 2016; Spary et al. 2014). Induced expression
of these molecules subsequently promotes increased sensitivity to killing by CTLs (Y. Lee et al.
2009; Filatenkov et al. 2015). In addition to local tumor control, radiation treatment has also
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been reported to drive antitumor abscopal effects when used in combination with immunotherapy
(Dewan et al. 2009; Niknam et al. 2018).
Though TREGS are known to suppress the killing activity of CTLs, the impact of radiation
treatment on TREG frequency, phenotype, and suppressive function is less clear. While several
murine studies have shown that TREGS are more radioresistant compared to other lymphocyte
populations it is less clear what effect it has on the phenotype and function of human TREGS (Qu,
Jin, et al. 2010; Baba et al. 2012). Moreover, functional studies in mice have been contradictory.
Studies by Qu et al found no difference in the suppressive function of TREGS from radiation
treated mice compared to control mice, in contrast to Balogh et al and Billiard et al who reported
decreased functional activity in irradiated TREGS (Qu, Zhang, et al. 2010; Balogh et al. 2013;
Billiard et al. 2011). In addition, studies by Muroyama et al and Kachikwu et al reported
increased TREG number in locally irradiated tumors compared to control mice, in vivo
(Muroyama et al. 2017; Kachikwu et al. 2011), while Cao et al (2009) and Liu et al observed a
decrease in human in vitro and murine whole-body tumor irradiated studies, respectively (Cao et
al. 2009; R. Liu et al. 2010). It seems plausible that some of the disparities in observations may
be due to differences between natural versus tumor-induced TREGS.
Here, we assessed the direct effect of radiation on viability and Foxp3 expression in
natural and induced human TREG cells. We also sought to determine the impact of radiation on
the suppressive function of induced TREGS as well as the expression of molecules associated with
functional TREG activity: CD25, CTLA-4, LAG-3, CD39, CD73, and PD-L1. Our data revealed
that radiation induces less death in human TREG cells as compared to conventional CD4+ T cells
and that radiation decreases expression of Foxp3 in both types of TREG cells. Additionally, we
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showed that iTREG cell phenotype is modulated by radiation and that cells are functionally less
suppressive following radiotherapy.
2.3

Materials & Methods

2.3.1 Human T cell isolation
Commercially available human peripheral blood mononuclear cells (PBMCs) were obtained
from healthy donors [HemaCare and ATCC]. PBMCs were purified from buffy coats by gradient
centrifugation using Lymphocyte Separation Medium [Corning]. PBMCs were rested overnight
in RPMI medium containing 10% FBS and 1% Penicillin/Streptomycin prior to T cell isolation
by magnetic activated cell sorting (MACS). The CD4+ T cell fraction was isolated by negative
depletion from total PBMCs using the human CD4+CD25+ Regulatory T Cell Isolation Kit
[Miltenyi Biotec] according to manufacturer’s instructions. CD25+ natural TREGS (nTREGS) were
subsequently positively selected for and separated from the CD4+CD25- naïve T cell population.
Cell purity was assessed by flow cytometry staining. Cells were cultured in 37oC incubator with
5% CO2 in TexMACS medium [Miltenyi Biotec]. nTREG and iTREG cells were supplemented with
500 U/mL and 100 U/mL of human recombinant IL-2 [Millipore], respectively.
2.3.2 iTREG differentiation
iTREG differentiation was performed as previously described (Schmidt et al. 2016). Briefly,
following MACS isolation, naïve T cells were rested for 2-8 hours before plating under iTREG
differentiation conditions at 1.1 to 1.5 x 105 cells/well in a 96U well plate. Cells were stimulated
with 5 µg/mL plate-bound anti-CD3 antibody [OKT3, NA/LE], 1 µg/mL soluble anti-CD28
antibody [CD28.2, NA/LE; BD Biosciences] and 100 U/mL IL-2. Cells stimulated with only
these reagents served as “mock” control cells. For iTREG differentiation, 5 ng/mL TGF-b1 [R&D
Systems] and 10 nM all-trans retinoic acid [Sigma-Aldrich] were additionally added. On day 3,
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100 µL of medium was removed and 100 µL of fresh medium plus growth supplements was
added. Cells were then incubated for an additional 3 days.
2.3.3 Irradiation
A RS-2000 biological X-ray irradiator [Rad Source Technology] was used to irradiate cells.
Irradiation was performed at a dose of 2 Gy/min at voltage 160 kV and 25 mA current. On day 6,
cells were washed and resuspended in fresh TexMACS medium without cytokines. Cells were
kept on ice and irradiated (5 Gy or 10 Gy) or mock-irradiated (0 Gy). Immediately following
irradiation, the culture medium was replaced with fresh medium plus growth supplements minus
anti-CD3 and anti-CD28.
2.3.4 Flow cytometry
Anti-human antibodies were used to characterize TREG cells following isolation: Foxp3-Pacific
Blue, Foxp3-PE [PCH101], Gata3-PE [TWAJ] and T-bet-PE [4B10; Invitrogen]; CD4-FITC,
LAG-3-PE, CD39-APC and CD73-APC [BD Biosciences]; CD4-APC, CD25-APC, CD25-PE,
CTLA-4-APC and PD-L1-APC [BioLegend]. Fixable Viability Stain 780 [BD Biosciences] was
used to exclude dead cells according to manufacturer’s instructions. Appropriate isotype control
antibodies were used, and gating was based on < 5% isotype staining. Intracellular staining was
performed using the Foxp3 Transcription Factor Staining Buffer Set [Invitrogen] according to
manufacturer’s instructions. Data was acquired on a BD Fortessa [Beckman Coulter] and data
was analyzed using FlowJo software [TreeStar].
2.3.5 In vitro proliferation assay
Responder T cell proliferation assay was performed as previously described with minor
modifications (Venken et al. 2007). Briefly, purified CD8+ T cells were labeled with 2.5 µM
carboxyfluorescein succinimidyl ester (CFSE) [BD Biosciences]. Labeled CD8s were cultured at
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a constant number of 6 x 104 cells/well either alone (1:0) or at a 4:1 ratio with either 0 Gy or 10
Gy treated iTREG cells 48hrs post radiation in a U-bottom 96-well plate with 5 µg/mL platebound anti-CD3 and 1 µg/mL anti-CD28 in TexMACS media for 4-5 days. Proliferation was
determined by CFSE dilution on the flow cytometer and analyzed using FlowJo software.
2.3.6 Statistical analysis
Statistical differences between groups were calculated using the Student t test or a one-way
ANOVA with Bonferroni test for multiple comparisons using GraphPad Prism software.
Statistical significance was defined as P £ 0.05. P values: *, P £ 0.05; **, P £ 0.01; ***, P £
0.001.
2.4

Results

2.4.1 Both natural TREG and induced TREG cells are more resistant to cell death by radiation
than CD4+ conventional T cells
It has been reported that TREG cells preferentially survive radiation treatment compared to
CD4+ conventional T (Tconv) cells in mice (Qu, Zhang, et al. 2010; Anderson et al. 2004;
Komatsu and Hori 2007). However, experiments utilizing human cells observed increased
sensitivity of TREGS to low dose radiation (< 2 Gy) (Cao et al. 2011). Most studies examining this
question have investigated the sensitivity of natural TREGS (nTREGS) alone or the total TREG
population, which potentially includes both natural and tumor induced TREGS. As such, the
specific radiosensitivity of induced TREG (iTREG) cells has not fully been explored. While both
nTREG and iTREG cells are functionally suppressive, Foxp3 expression is reportedly unstable in
iTREGS (Floess et al. 2007). Therefore, it is plausible that nTREGS may have different sensitivities
than TREGS induced in the periphery by tumors. Thus, we first compared the sensitivities of
natural and induced human TREGS to determine if there were differences in susceptibility to cell
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death following exposure to radiation. We isolated CD4+CD25+ nTREG cells from human
peripheral blood mononuclear cells (PBMCs) as described in the Material and Methods. To
induce a TREG phenotype, naïve CD4+ T cells were cultured in the presence of TGF-b1 and
ATRA for 6 days which results in expression of Fox3 and other TREG associated genes (Schmidt
et al. 2016). nTREG, iTREG, or CD4+ Tconv cells were subsequently exposed to low doses of
radiation (5 Gy or 10 Gy) and evaluated 48 hours post-treatment for cell death. While CD4+
Tconv cells exhibited significant increases in death after radiation, both nTREG and iTREG cells had
lower relative amounts of cell death (Fig. 2.1). These results support the idea that human TREG
cells are more radioresistant as compared to CD4+ Tconv cells.
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Figure 2.1 TREGS more radio-resistant than CD4+ T cells.
(A) Purified CD4+ conventional T cells or nTREGS were exposed to 5 Gy of radiation or mock
irradiated (0Gy). After 48hrs, cells were stained with Annexin V and 7-AAD and analyzed by
flow cytometry. (B) TGF-β1-induced TREGS or CD4+ Tconv cells were treated with 10 Gy of
radiation or mock irradiated. 48hrs post treatment cells were stained with a fixable viability dye
(FVS) and CD4 or FVS, CD4, CD25, and Foxp3 to denote CD4+ Tconv and iTREG cells,
respectively. Data are representative of three independent experiments. Error bars represent
SEM. *P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001 by paired, one-tailed Student t test.
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2.4.2 Radiation decreases Foxp3 expression more robustly in iTREGS as compared to nTREGS
TREG cells express the transcription factor Foxp3, a master regulator essential for their
development and suppressive function (Shimon Sakaguchi et al. 2008). Several groups have
reported different effects of radiation on Foxp3 expression. Murine studies have reported both an
increase (Muroyama et al. 2017; Kachikwu et al. 2011) and decrease (R. Liu et al. 2010) in TREG
frequency following radiation while a human study noted a reduction in CD4+CD25+ TREG cells
(Cao et al. 2009). Similar to reports describing radiations impact on TREG radiosensitivity, most
of the studies examining FoxP3 expression were performed in mice. Additionally, in vivo
experiments in disease settings evaluated the total TREG population, which likely contain both
nTREG and iTREG cells, while human experiments assessed only the nTREG cell population. We
therefore evaluated human natural and induced TREGS for Foxp3 expression following exposure
to low dose radiation, in vitro. Foxp3 expression in CD4+CD25+ nTREGS decreased after
treatment with 10 Gy (Fig. 2.2A). FoxP3 was expressed in 88% of untreated cells on average and
decreased to 68% in cells treated with radiation across 3 independent experiments (Fig. 2.2B).
More cells expressed CD25 in iTREGS as compared to nTREGS, however FoxP3 expression was
still decreased by radiation within these cells (Fig. 2.2C). Foxp3 was detected in 38% of
untreated iTREGS and was reduced to 8% following radiation across independent experiments
(Fig. 2.2D). Interestingly, iTREGS showed a more robust decrease in Foxp3 expression when
compared to nTREGS. iTREG cells are characterized as expressing high levels of CD25. Evaluation
of the CD4+CD25hi population of iTREGS revealed that Foxp3 was more highly expressed in the
untreated cells (69% on average) and that radiation significantly decreased Foxp3 expression
within CD25hi iTREGS down to 10% (Fig. 2.2E). Interestingly, the magnitude of decreased Foxp3
expression was greater within the CD25hi population as compared to that observed in the total
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CD25+ iTREG population. Compared to untreated cells, both nTREGS and iTREGS showed a
significant decrease in Foxp3 expression 48 hours after exposure to 10 Gy. Furthermore, the
percent of total CD4+ T cells remained unchanged (data not shown) within iTREGS suggesting
that radiation specifically downregulates the expression of Foxp3 and that iTREG cells were more
sensitive to this effect.
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Figure 2.2 Radiation decreases Foxp3 expression in natural and induced human
CD4+CD25+ TREGS.
Natural and induced TREG cells were mock irradiated or exposed to 10 Gy of radiation. (A) After
48hrs, nTREGS were stained for expression of CD4 and CD25 by flow cytometry. (B) Expression
of Foxp3 was evaluated within the CD4+CD25+ population. (C) 48hrs after irradiation, TGF-β1induced TREGS were stained for expression of CD4 and CD25 by flow cytometry. (D) Expression
of Foxp3 was evaluated within the total CD4+CD25+ population. (E) iTREGS were evaluated for
the expression of Foxp3 within the CD4+CD25hi population. Data are representative of three
independent experiments. Error bars represent SEM. *P ≤ 0.05 by paired, one-tailed Student t
test.
2.4.3 Irradiated iTREGS are not converted to another T cell subset following loss of Foxp3
Plasticity is a unique characteristic of CD4+ T cells, allowing them to differentiate from
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one T helper (TH) subset to another when exposed to the right cytokine milieu (L. Zhou, Chong,
and Littman 2009). Additionally, epigenetic changes in transcription factor activity induce
changes in the type of CD4+ T cell needed for the appropriate immune response (Wei et al.
2009). Foxp3 is induced in regulatory T cells to limit cell cytotoxicity and autoimmunity
(Haribhai et al. 2011). The transcription factors T-box transcription factor (T-bet) and GATA
binding protein 3 (GATA3) drive TH1 and TH2 differentiation, respectively (Chakir et al. 2003).
Because changes in the microenvironment can directly influence the phenotype of local CD4+ T
cells (Butcher et al. 2016), we wanted to determine if irradiated iTREGS were being converted into
another TH subset upon downmodulation of Foxp3 expression. While radiation robustly reduced
Foxp3 expression in iTREG cells, expression of TH1-associated T-bet or TH2-associated GATA3
did not exhibit a compensatory increase in expression 48 hours post-treatment (Fig. 2.3).
Interestingly, while T-bet expression was low and remained low after radiation, GATA3
expression was detected in a subpopulation of the cultured cells and its expression was also
reduced by radiation. These data suggest that while radiation can reduce expression of
transcription factors in CD4+ T cells, irradiated iTREG cells are not converted to a TH1 or TH2
subset but instead can be described as an “ex-Foxp3+” CD4+ T cell.
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Figure 2.3 Irradiated iTREGS are not converted to a TH1 or TH2 subset after radiation.
Induced TREG cells were mock irradiated or exposed to 10 Gy of radiation. (A) iTREGS were
analyzed 48hrs post-treatment for CD25 and Foxp3, T-bet, or GATA3 expression within CD4+
T cells. Representative plots of CD4+ T cells and (B) mean frequency of each subset. Data are
representative of three independent experiments. Error bars represent SEM. *P ≤ 0.05 by paired,
one-tailed Student t test.
2.4.4 Radiation induces differential changes in signature TREG molecules
Aside from Foxp3, TREG cells express several signature molecules associated with their
regulation and functional activity. CD25, the high-affinity IL-2 receptor, is highly expressed by
iTREGS. CD25 is also regulated by Foxp3 through binding at the Cd25 promoter thus enhancing
its expression (Camperio et al. 2012). Because we observed a decrease in Foxp3 following
radiation treatment we wanted to determine if CD25 expression was also reduced. When iTREGS
were evaluated for CD4+CD25+ double positive cells we observed a significant decrease in
CD25 expression in irradiated iTREGS as compared to untreated cells (Fig. 2.4A). This was
observed within the total CD25+ population as well as the CD25hi cells. In contrast, while CD25
expression was reduced in irradiated CD4+ Tconv cells compared to untreated cells, the change
was not as significant as that observed in iTREGS (Fig. 2.4B). Because CD4+CD25hi iTREG cells
had the highest frequency of Foxp3+ cells we further evaluated this cell population for the
expression of other surface proteins associated with TREG suppressive function. Cytotoxic T
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lymphocyte antigen 4 (CTLA-4) and lymphocyte activation gene 3 (LAG-3) have been shown to
block dendritic cell maturation and inhibit effector T cell proliferation (Huang et al. 2004; Kolar
et al. 2009; Onishi et al. 2008; Liang et al. 2008). Concordant expression of the ectoenzymes
CD39 and CD73 suppress effector T cell function by converting ATP into adenosine (Deaglio et
al. 2007). Furthermore, the presence of PD-L1+ TREGS has been correlated with exhausted
effector T cells and a suppressive tumor microenvironment (S. P. Wu et al. 2018). Similar to
CD25, CTLA-4 and LAG-3 have been reported to be regulated by Foxp3 (Xie et al. 2015;
Sadlon et al. 2010) thus we wanted to determine if their expression would also be reduced
following radiation. Radiation significantly down-regulated the expression of CTLA-4 in
CD4+CD25hi iTREGS from 57% to 44% (Fig. 2.4C). In contrast, LAG-3 (34% to 48%) (Fig. 2.4D)
and CD73 (20% to 28%) (Fig. 2.4F) were moderately upregulated following treatment.
Interestingly, radiation had no effect on the expression of CD39 (Fig. 2.4E) and PD-L1 (Fig.
2.4G). These results suggest that radiation-induced modulation of iTREG-associated suppressive
proteins may not be strictly dependent on Foxp3 regulation or that LAG-3 expression may be
regulated by other mechanisms in iTREGS following radiation treatment.
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Figure 2.4 Phenotypic modulation of CD4+CD25hi iTREGS by radiation.
(A) iTREGS and (B) CD4+ Tconv cells were mock irradiated or exposed to 10 Gy of radiation.
48hrs post treatment CD4+ cells were analyzed for expression of CD25 by flow cytometry. Live
cells were gated on CD4+CD25hi and the expression of (C) CTLA-4, (D) LAG-3, (E) CD39, (F)
CD73, and (G) PD-L1 was evaluated 48hrs after radiation; mean of target proteins shown below
(C-G). Data are representative of three independent experiments. Error bars represent SEM. *P ≤
0.05; ** P ≤ 0.01; *** P ≤ 0.001 by paired, two-tailed Student t test.
Not all cells in the CD4+CD25hi population were Foxp3 positive (Fig. 2.2E) so we next
evaluated changes to TREG suppressive molecules within Foxp3+ cells following radiation
treatment. For this analysis iTREGS were defined as CD4+Foxp3+ (Fig. 2.5A) and the expression
of suppressive molecules after radiation was measured. PD-L1 was expressed in over 80% of
CD4+Foxp3+ iTREG cells while CD39 was expressed in about 30% of cells. 48hrs post-radiation
we saw little change in CD39 (Fig. 2.5E) and PD-L1 (Fig. 2.5G) expression. Similar to the
change detected in CD4+CD25hi cells (Fig. 2.4C), CD25 (Fig. 2.5B) and CTLA-4 (Fig. 2.5C)
expression also decreased upon radiation in CD4+Foxp3+ cells though the modulation did not
reach statistical significance. We detected a significant increase in LAG-3 expression from 24%
to 29% (Fig. 2.5D), as well as an increase in CD73 that neared statistical significance (Fig. 2.5F).
Overall, analysis of both CD4+FoxP3+ and CD4+CD25hi iTREGS revealed that radiation reduced
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expression of CTLA-4 and CD25, while conversely increasing expression of LAG-3 and CD73.
However, no change in the expression of CD39 or PD-L1 was induced by in vitro irradiation in
either cell population.
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Figure 2.5 Phenotypic modulation of CD4+Foxp3+ iTREGS by radiation.
(A) iTREGS were mock irradiated or exposed to 10 Gy of radiation. 48hrs post treatment
CD4+Foxp3+ cells were analyzed for expression of (B) CD25, (C) CTLA-4, (D) LAG-3, (E)
CD39, (F) CD73, and (G) PD-L1. Data are representative of two-three independent experiments.
Error bars represent SEM. *P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001 by paired, two-tailed Student t
test.
2.4.5 Radiation inhibits suppressive activity of iTREGS
We observed that radiation treatment reduces the expression of Foxp3 in iTREG cells and
that the expression of molecules associated with their functional capacity to suppress other
immune cells is modulated both positively and negatively post treatment (decreased expression
of CD25 and CTLA-4 versus increased expression of LAG-3 and CD73). Thus, we wanted to
directly investigate whether irradiated iTREG cells retained their suppressive function. We
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compared the ability of irradiated and non-irradiated iTREGS to inhibit CD8+ T cell proliferation.
48hrs after treatment with radiation, viable iTREGS were counted and co-incubated with
autologous CFSE-labeled CD8+ T cells at a ratio of 1:4. Cells were co-cultured together for 4-5
days and CD8+ T cell proliferation was measured by CFSE dilution. CD8+ T cells had a mean
proliferation rate of 92% in the presence of 10 Gy treated iTREGS, as compared to only 72%
following co-culture with non-irradiated iTREG cells (Fig. 2.6).
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Figure 2.6 Irradiated iTREGS exhibit reduced suppressive capacity.
CFSE-labeled CD8+ T cells were stimulated with CD3 and CD28. Irradiated or non-irradiated
iTREGS were co-incubated with stimulated CD8+ T cells at a ratio of 1:4 for 4-5 days. (A)
Histogram overlay displaying CD8+ T cell CFSE dilution in the presence of 0 Gy (middle
portion of plot) or 10 Gy treated iTREGS (bottom portion of plot) at a suppressor:responder ratio
of 1:4. CD8 alone division is displayed in top portion of plot. (B) Percentage of divided CD8+ T
cells cultured with mock or 10 Gy treated iTREG cells or alone. Data are representative of two
independent experiments. Error bars represent SEM. *P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001 by a
one-way ANOVA with Bonferroni test for multiple comparisons.
2.5

Discussion
Radiotherapy is a common treatment modality for cancer and lower doses can effectively

enhance antitumor immune responses by modulating tumor phenotypes (Kumari et al. 2016).
However, the effect of radiation directly on TREG viability, phenotype, and function remains
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controversial and less well evaluated in human cells. In this study, we compared the effect of
radiation treatment on human natural versus induced TREG cell viability and expression of Foxp3.
Furthermore, we examined iTREGS for radiation-induced changes in cell phenotype and
suppressive capacity. We show that irradiated nTREG and iTREG cells are more viable than
conventional CD4+ cells and that CD4+CD25+ TREG cells exhibit decreased expression of Foxp3
after exposure to ionizing radiation. Additionally, we demonstrated that iTREG cell phenotype is
differentially modulated following radiation treatment and that their suppressive function is
inhibited.
Earlier reports in mice showed that TREGS are more resistant to radiation treatment (Qu,
Jin, et al. 2010; Komatsu and Hori 2007). Our results in human cells are in line with previously
reported data that TREG cells are more resistant to radiation-induced cell death as compared to
CD4+ TCONV cells. Additionally, we found that this resistance was seen in both nTREG and iTREG
cells. However, these results contrast those previously observed in other studies of human TREGS
(Cao et al. 2011). A significant factor that could explain this discrepancy in human TREG viability
is radiation dose. Previous reports exposed TREGS to low doses of radiation (0.94 Gy and 1.875
Gy) resulting in significantly more cell death in TREGS as compared to CD4+ TCONV cells (Cao et
al. 2011). In contrast, our study utilized higher radiation doses (5 Gy and 10 Gy) which showed a
marked increase in CD4+ TCONV cell death compared to both nTREG and iTREG cells (Fig. 2.1).
Radiation reportedly decreases human CD4+ T cell viability in a dose-dependent manner
(Nakamura, Kusunoki, and Akiyama 1990), cells exposed to 5 Gy of radiation exhibited a robust
decrease in live cells not seen in cells treated with ≤ 2 Gy. Therefore, it is plausible that human
TREGS are more resistant to higher radiation doses whereas low dose radiation does not induce
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significant death in CD4+ TCONV cells. Doses above 2 Gy are more commonly used in cancer
therapy than those below 2 Gy.
Much of what is known about TREG phenotype and functional activity has been derived
from murine models. However, little research has been conducted to elucidate if similar trends
are observable in human cells. Thus, conflicting reports regarding the effect of radiation
treatment on TREG cells could be attributed to the use of murine versus human cells. Moreover,
different experimental designs have been used. When evaluating TREG frequency in murine
models, the use of whole-body versus local radiation treatment could have a profound effect on
both overall TREG number and observed functional capacity. Mice treated with low-dose total
body irradiation exhibited a decrease in the frequency and total number of nodal CD4+Foxp3+
TREG cells (R. Liu et al. 2010), while mice that received local irradiation were found to increase
the proportion of tumoral and splenic TREGS (Kachikwu et al. 2011; Muroyama et al. 2017). In
addition, TREGS from locally irradiated mice retained their suppressive function.
It is important to distinguish natural versus induced TREG cells. Though phenotypically
similar, nTREG and iTREG cells display distinctly different regulatory functions (Haribhai et al.
2011). Despite this fact, we are unaware of studies to elucidate if radiation-induced modulations
observed are attributed to natural and/or induced TREGS. Here, our focus was on human TGF-b1induced TREG cells which would be similar to the tumor-induced TREGS exposed to radiation as a
part of cancer treatment. The reason for the differential observations remains unclear, however it
is possible that the composition of natural versus induced TREGS within the experimental systems
may have an impact on the frequency of TREG cells observed.
Several groups have reported both an increase and decrease in TREG frequency when
exposed to radiation (Muroyama et al. 2017; Kachikwu et al. 2011; R. Liu et al. 2010; Cao et al.
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2009). Our findings showed a significant decrease in human TREG cells 48 hours post treatment
in vitro. Importantly, this decrease was observed in nTREG and iTREG cells as indicated by
downregulation of Foxp3 expression (Fig. 2.2A-D). Among iTREGS, this decrease was observable
regardless of whether Foxp3 was analyzed among total CD25+ or CD25hi T cells (Fig. 2.2D-E).
Though iTREGS downregulated Foxp3, this did not correlate to an increase in the TH1 or TH2associated transcription factors T-bet and GATA3, respectively (Fig. 2.3). These results are
significant because they suggest that radiation is not converting iTREGS into another CD4 subtype
and that CD4 expression is not affected.
Phenotypically, Foxp3 is not the sole protein characterizing TREGS. High expression of
CD25, as well as expression of CTLA-4, CD39, CD73, and LAG-3 have all been reported to be
expressed by TREGS. Additionally, some groups have reported the presence of PD-L1 on TREGS in
tumor models (S. P. Wu et al. 2018). To our knowledge, the effect radiation has on the
expression of many of these molecules in TREGS has not been reported, particularly in human
derived iTREG cells. TREG cells are commonly defined as being Foxp3+ and CD25hi. We therefore
compared the phenotype of iTREGS defined as either CD4+CD25hi or CD4+Foxp3+. These
experiments revealed that either phenotypic characterization of iTREGS displayed similar trends in
protein expression after radiation treatment (Fig. 2.4 and Fig. 2.5). Both gating strategies showed
a decrease in CD25 and CTLA-4 while LAG-3 and CD73 expression increased. Lastly, CD39
and PD-L1 expression was unchanged with radiation treatment as assessed by either strategy.
This observation is particularly noteworthy because it suggests that as Foxp3 regulated genes,
CD25 and CTLA-4 expression may be directly tied to Foxp3 expression.
In addition to CD25 and CTLA-4, LAG-3 is also reported as being regulated by Foxp3
(Xie et al. 2015). Interestingly, we observed an increase in LAG-3 expression following low
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dose radiation as opposed to the decrease seen in CD25 and CTLA-4 expression (Fig. 2.4 and
Fig. 2.5). Similarly, chemoradiation was shown to increase the proportion of CD4+LAG-3+
expressing T cells in head and neck cancer patients (Sridharan et al. 2016). It is not clear how
radiation treatment upregulates the expression of LAG-3 in iTREGS. It is possible that radiation is
directly altering expression of this gene via epigenetic mechanisms as has been reported for
expression of some immune relevant genes in irradiated tumor cells (Kumari et al. 2013),
however further exploration into this possibility is needed. In addition, previous studies of
irradiated human nTREG cells noted enhanced expression of glucocorticoid-induced tumor
necrosis factor receptor (GITR), another Foxp3 regulated gene (Cao et al. 2009). These
observations combined with our results greatly suggest that Foxp3-associated genes may be
regulated by other mechanisms other than Foxp3 following radiation.
A possible orchestrator could be the transcription factor early growth response gene 2
(Egr2). Egr2 has been shown to convert naïve CD4+ T cells into LAG-3-expressing TREGS
(Okamura et al. 2009). Notably, these LAG-3-expressing TREGS were characterized as being
Foxp3-. Our study demonstrates that radiation induces a CD4+Foxp3- T cell subset from
CD4+CD25hiFoxp3+ iTREGS (“ex-Foxp3+ cells”). iTREG cell conversion in our study focused on
possible plasticity and conversion towards a TH1 or TH2 subset. However, it is plausible that
radiation treatment could convert Foxp3+ iTREGS to another regulatory T cell subset. Though
LAG-3 expression has been reported to confer Foxp3+ regulatory T cells with greater
suppressive capacity (Huang et al. 2004; Liang et al. 2008), we found that irradiated iTREG cells
were functionally less suppressive as compared to untreated cells (Fig. 2.6) despite an increase in
LAG-3 expression. This is in line with reports that showed Egr2-transduced CD4+ T cells, which
positively expressed LAG-3 and IL-10, insufficiently suppressed proliferation of responder T
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cells in vitro (Okamura et al. 2009). Subsequent in vivo studies were able to demonstrate the
suppressive capacity of Egr2-transduced CD4+ T cells which could suggest functional
differences in LAG-3 activity in vitro versus in vivo.
LAG-3 on CD4+ and CD8+ TCONV cells inhibits their expansion and effector function
(Durham et al. 2014; Grosso et al. 2007). However, it isn’t entirely clear how LAG-3 signaling
impacts TREGS. In a murine model of Type 1 diabetes LAG-3 was shown to limit TREG function
(Q. Zhang et al. 2017). Anti-LAG-3 blocking antibodies are currently being used in preclinical
studies and phase 1 clinical trials in combination with anti-PD-1. Recent studies have revealed
that dual treatment with anti-LAG-3 and anti-PD-1 blocking antibodies significantly enhances
the proliferation of CD4+ and CD8+ TCONV cells (Lichtenegger et al. 2018). Therefore, the
combined use of radiotherapy and anti-LAG-3 blocking antibodies could greatly enhance the
antitumor immune response in preclinical studies. However, it seems plausible that antagonistic
antibodies that prevent LAG-3 signaling may enhance TREG suppressive function at the same
time that they are promoting effector T cell activity. Further studies are needed to elucidate the
effect LAG-3 has on TREG suppressive function.
It has been reported that the suppressive function of iTREG cells is conferred by the
expression of Foxp3 (Hori, Nomura, and Sakaguchi 2003), however it is unclear which
suppressive mechanism(s) have been arrested in irradiated iTREGS. In this study we showed that
radiation is capable of modulating the expression of Foxp3 and several iTREG suppressive surface
molecules, though it is also possible that radiation also induces changes in TREG associated
cytokines, TGF-b1 and IL-10, which could be evaluated in further investigations.
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2.6

Conclusion
In summary, our study found that both human nTREG and iTREG cells are more resistant to

radiation-induced cell death and that radiation treatment reduces their expression of Foxp3. In
addition, we demonstrate that radiation modulates iTREG cell phenotype and inhibits their
suppressive activity. This data provides a rationale for the use of radiation in combination with
current immunotherapies to increase antitumor immune responses by specifically targeting
Foxp3+ iTREG cell function.
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3

CHARACTERIZATION OF THE IMPACT OF RADIOTHERAPY ON
REGULATORY T CELLS AND THE TUMOR MICROENVIRONMENT IN
DIVERSE MURINE TUMOR MODELS

3.1

Abstract
The impact of radiation on TREG cells remains controversial. Sub-lethal radiation has been

shown by our lab and others to alter the phenotype of human tumor cells by enhancing their
expression of the co-stimulatory molecules OX40L and 4-1BBL. Signaling through both OX40
and 4-1BB have been reported to reduce TREG frequency and function. We therefore examined
whether radiation-induced modulation of OX40L and 4-1BBL in murine tumor cells could
influence the frequency of TREG cells in tumor bearing mice. In addition, we evaluated
differences in OX40L and 4-1BBL expression in two widely used murine tumor models for these
experiments. 4T1 mammary and MC38 colorectal cells were implanted subcutaneously into mice
and treated locally with 8-10 Gy of radiation. We found that radiation differentially modulated
the expression of OX40L and 4-1BBL among the two tumor models, however this expression
did not appear to correlate with the observed reduction in TREG frequency seen in both tumor
models. Further analysis aimed to assess differences in immune cell composition induced by
radiation. We show that CD8+ effector T cells were increased in irradiated 4T1 but not in MC38
tumors. Further, we show that radiation induces differential changes in the immune cell gene
profile among 4T1 and MC38 tumor models. Overall, our data suggests that radiation-induced
changes in tumor expressed OX40L and 4-1BBL do not mediate changes in TREG frequency
within tumors. Moreover, this study highlights that differences in the tumor microenvironment
and immune cell profile may contribute to variations in therapeutic responses of various murine
models utilizing radiation.
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3.2

Introduction
T cell immunity is an important factor in the elimination of tumor cells and inhibiting

tumor growth. T cell activity can be inhibited by signals through T cell checkpoint proteins such
as CTLA-4 and PD-1. The use of immunotherapeutic agents such as anti-CTLA-4 and anti-PD1/PD-L1 blocking antibodies can effectively enhance anti-tumor responses (Curran et al. 2010;
Fransen et al. 2013; Selby et al. 2013). Unfortunately, checkpoint blocking antibodies only
benefit a small percentage of patients and are not always effective (Fares et al. 2019). A major
contributor of tumor escape is the presence of immunosuppressive cells within the tumor
microenvironment including regulatory T (TREG) cells. TREGS are a suppressive subset of CD4+ T
cells that negatively regulate anti-tumor immunity. These cells function by inhibiting dendritic
cell maturation and cytotoxic T lymphocyte (CTL) effector activity (Liang et al. 2008; Onishi et
al. 2008; McNally et al. 2011; Bauer et al. 2014). Thus, the selective removal of TREG cells or
reduction in their suppressive capacity, as well as increasing CTLs could greatly enhance antitumor activity.
OX40 and 4-1BB are T cell co-stimulators belonging to the tumor necrosis factor
superfamily that bind to OX40L and 4-1BBL, respectively (Croft 2009). Expression of OX40L
and 4-1BBL is induced on professional antigen presenting cells, CD4+ T cells, and CD8+ T
cells, as well as endothelial cells and smooth muscle cells under inflammatory conditions. OX40
and 4-1BB are inducibly expressed on activated CD4+ and CD8+ T cells and are involved in the
promotion of effector T cell clonal expansion, survival, and cytokine induction (Croft 2009;
Vinay and Kwon 2012). Conversely, signaling through both OX40 and 4-1BB have been shown
to inhibit the conversion of naïve CD4+ T cells into TREGS, abrogate Foxp3 expression, and
inhibit TREG suppressive function (Vu et al. 2007; Xiao et al. 2008; Kitamura et al. 2009; Smith,
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Hoeizinger, and Dominguez 2011; Madireddi et al. 2012; X. Zhang et al. 2018). These are
important signals for promoting tumor immunity and treatment of tumor-bearing mice with
agonist antibodies to OX40 and 4-1BB have been reported to induce effective anti-tumor
immune responses and decrease the activity of murine TREG cells (Gough et al. 2008; Curran et
al. 2011; Smith, Hoeizinger, and Dominguez 2011; Barsoumian, Yolcu, and Shirwan 2016).
Radiation has been shown to induce the expression of OX40L and 4-1BBL in several human
tumor cells (Bernstein et al. 2014; Kumari and Garnett-Benson 2016). Additionally, we
previously reported that radiation-induced modulation of OX40L and 4-1BBL on human
colorectal tumor cells increased killing by CTLs (Kumari and Garnett-Benson 2016), however it
is unknown how such changes effect TREG cells. Therefore, this study was designed to test the
hypothesis that radiation-induced modulation of tumor expressed OX40L and 4-1BBL reduces
TREG number.
In addition, data regarding the efficacy of radiotherapy in combination with cancer
immunotherapies, and the impact of radiation on T cell frequencies, has been based on
observations in pre-clinical murine tumor models. Much of this data comes from two of the most
commonly used tumor models, 4T1 and MC38. Here we also investigate differences in OX40L
and 4-1BBL expression, as well as differences in the immune cell profile between these model
systems. Our data revealed that radiation differentially modulates the expression of OX40L and
4-1BBL in 4T1 and MC38 tumor cells. Data also revealed that TREGS are significantly reduced
with radiation in both tumor models despite marked differences in OX40L and 4-1BBL
expression between these models, suggesting that signaling through these molecules is not likely
contributing to the reduction in TREGS observed. Additionally, we showed that radiation
differentially modulates the immune cell profile of 4T1 and MC38 tumors.
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3.3

Materials & Methods

3.3.1 Tumor cell lines
Murine 4T1 (breast) and MC38 (colon) carcinoma cell lines were obtained from LTIB, NCI,
NIH. Cells were cultured according to ATCC recommendations and periodically tested to ensure
the absence of Mycoplasma. Cells were cultured at 37oC with 5% CO2.
3.3.2 Irradiation of cells in vitro
A RS-2000 biological X-ray irradiator [Rad Source Technology] was used to irradiate cells and
mice. Irradiation was performed at a dose of 2 Gy/min by setting irradiator voltage to 160 kV
and current to 25 mA. Tumor cells were washed and resuspended in fresh culture medium. Cells
were kept on ice and irradiated (5 Gy or 10 Gy) or mock-irradiated (0 Gy). Immediately
following irradiation, culture medium was replaced with fresh medium.
3.3.3 Irradiation of tumor-bearing mice
6-8 week old BALB/c or C57BL/6 mice were purchased from Charles River Laboratories.
C57BL/641BBnull mice were generated in-house. Mice were injected subcutaneously (s.c) in the
right hind leg with 8 x 105 4T1 or 3 x 105 MC38 cells in 100 uL of 1x PBS. Tumor growth was
measured every 2-3 days. When tumors reached 200-400 mm3 mice were anesthetized using a
cocktail of 100 mg/kg ketamine and 10 mg/kg xylazine before being locally irradiated (8 Gy) or
mock-irradiated (0 Gy). Mice were restrained in a plexi-glass jig [Braintree Scientific] and
placed under a lead shield such that only the tumor-bearing leg was exposed to radiation. Mice
were sacrificed 24-48 hours post-irradiation and tumors harvested. Tumor samples were also
flash frozen in O.C.T. Compound [Tissue-Tek] and sectioned for fluorescence microscopy
staining or formalin fixed [Anatech].
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3.3.4 Flow cytometry
Anti-mouse antibodies used: OX40L-APC and 4-1BBL-PE [BioLegend]. Appropriate isotype
control antibodies were also used. Data was acquired on a BD Fortessa [Beckman Coulter].
FACS data was analyzed using FlowJo software [TreeStar].
3.3.5 Quantitative real-time PCR
mRNA was isolated from formalin-fixed paraffin embedded tumor tissue sections using the
RNeasy FFPE Kit [Qiagen] according to manufacturer’s instructions. mRNA concentration was
measured using a NanoVue nanodrop [GE Healthcare]. cDNA was synthesized using 300ng of
mRNA and amplified using the Maxima First Strand cDNA Synthesis Kit for RT-qPCR [Thermo
Scientific] according to manufacturer’s instructions. qPCR was conducted using TaqMan gene
expression assay [OX40L: Mm00437214; EIF1: Mm00783932_s1; Applied Biosystems]. Genespecific primer sequences to mouse 4-1BBL were adopted from (Devarapu et al. 2017). The
primers for mouse 4-1BBL consisted of forward primer (5’GCGTTGTGGGTAGAGGAGCAAA-3’) and reverse primer (5’CCAAGTACCTTCTCCAGCATAGG-5’) [GenBank: NM_009404]. Primers were obtained
from Integrated DNA Technologies. All samples were run in duplicate. Data were collected
using a 7500 Real Time PCR System and analyzed using the comparative DDCt method (Livak
and Schmittgen 2001). Target genes were normalized to the eukaryotic translation initiation
factor 1 (EIF1) housekeeping gene. Expression levels of target genes were compared between
non-irradiated and irradiated samples.
3.3.6 Fluorescence microscopy
Frozen tumor tissue sections were fixed with 4% paraformaldehyde at -20oC for 10 minutes and
washed twice with mQH2O. To conserve reagents, a hydrophobic barrier was drawn around each
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tissue section. Tissue was blocked with 2% BSA in PBS in a humidified chamber on rocker for 1
hour at room temperature. After washing 3 times with TBS, tissues were surfaced stained by
incubating with anti-rat CD4 [clone GK1.5; Thermo Scientific] or anti-rabbit CD8a [Santa Cruz
Biotechnology] unconjugated antibodies overnight on rocker at 4oC. Tissues were washed 3
times before secondary antibody staining with Alexa Fluor 488 [Invitrogen] for 1 hour at room
temperature followed by 3 additional washes. Intracellular staining was subsequently performed
following fixation with 4% paraformaldehyde and blocking with 2% BSA in TBS containing
0.05% Tween-20 (TBST). Tissue was incubated with anti-mouse/rat Foxp3-eFluor 570 [clone
FJK-16s; Invitrogen] overnight on rocker at 4oC. Slides were mounted with DAPI FluoromountG [SouthernBiotech] to distinguish nucleated cells. Images were acquired using a LSM700
confocal microscope [Zeiss]. 10 image fields per tumor section were randomly selected on
Foxp3 (TREG/CD4+ T cell analysis) or DAPI (CD8+ T cell analysis). The number of positive
cells per image field were manually counted and the average recorded.
3.3.7 NanoString
mRNA was isolated from formalin-fixed paraffin embedded tumor tissue sections using the
RNeasy FFPE Kit [Qiagen] according to manufacturer’s instructions. mRNA concentration was
measured using a NanoVue nanodrop [GE Healthcare]. Genes were quantified using an nCounter
system (NanoString Technologies).
3.3.8 Statistical analysis
Statistical differences between groups were calculated using the paired or unpaired, one-tailed or
two-tailed Student t test or a one-way ANOVA with Bonferroni test for multiple comparisons
using GraphPad Prism software. Statistical significance was defined as P £ 0.05. P values: *, P £
0.05; **, P £ 0.01; ***, P £ 0.001.
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3.4

Results

3.4.1 Radiation differentially modulates the expression of OX40L and 4-1BBL on murine
tumor cells
Studies have shown that radiation treatment can modulate the expression of costimulatory molecules, including OX40L and 4-1BBL on human tumor cells from solid tumors
including prostate, colorectal, and breast (Garnett et al. 2004; Bernstein et al. 2014; Kumari and
Garnett-Benson 2016; unpublished data) and that expression of these proteins can significantly
impact T cell activity. To expand upon these findings, we utilized two commonly used murine
tumor models to investigate if radiation also effects the phenotype of tumors in vivo. Colorectal
cancer is the 3rd leading cause of cancer-related death in U.S. men and women. Additionally,
breast cancer remains the 2nd leading cause of cancer-related death in women indicating the
continued need to develop effective treatments. MC38 colon and 4T1 breast are two murine
tumor models often used to give insight into treatment of these diseases. We began by evaluating
these murine tumor cells for changes in OX40L and 4-1BBL expression following in vitro
irradiation to see if they would respond similarly to human cells treated in vitro. We exposed
4T1 breast and MC38 colon tumor cell lines to 5 Gy and 10 Gy of radiation and assessed costimulatory molecule expression levels 48hrs post treatment. OX40L was moderately expressed
in untreated 4T1 cells (63%) while protein expression was lower in MC38 cells (26%) (Fig.
3.1A). OX40L expression was slightly reduced in 4T1 cells treated with 10 Gy (56%). Minimal
change in OX40L was observed in treated MC38 cells. We further analyzed cells for changes in
protein density by MFI. Following exposure to radiation, we observed a dose-dependent trend
towards an increase in the density of OX40L expression in both 4T1 and MC38 cell lines though
it did not reach statistical significance (Fig. 3.1B). 4-1BBL was highly expressed in both
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untreated 4T1 and MC38 tumor cell lines, 100% and 99%, respectively (Fig. 3.1C). Radiation
treatment had minimal effect on the frequency of 4T1 cells expressing 4-1BBL, however a slight
decrease was observed in MC38 tumor cells. Interestingly, 4-1BBL was expressed at a higher
density in 4T1 cells compared with MC38 cells (Fig. 3.1D). Tumor cells treated with 10 Gy of
radiation showed an increase in the density of 4-1BBL, with expression in MC38 cells reaching
statistical significance. However, we noted little to no change in 4-1BBL expression following
exposure to 5 Gy which may indicate that higher radiation doses are needed to upregulate its
expression. Overall, a higher frequency of 4T1 cells express OX40L compared to MC38 while
both cell lines express high levels of 4-1BBL. These results indicate that similar to published
reports in human cells, radiation can modulate the surface densities of OX40L and 4-1BBL costimulatory molecules on murine tumor cells, but expression is differentially modulated by cell
line and radiation dose.
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Figure 3.1 Role of radiation on tumor cells differs by model, in vitro.
4T1 and MC38 tumor cells were exposed to 5 Gy and 10 Gy of radiation or mock irradiated (0
Gy). (A) After 48hrs, cells were stained for expression of OX40L by flow cytometry. FMO
control staining is shown in orange filled histogram. OX40L positive cells are shown in red lined
histogram. Representative plots and (B) MFI. (C) Representative plots of tumor cells were
stained for expression of 4-1BBL and (D) MFI. Data are representative of two-three independent
experiments. Error bars represent SEM. *P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001 by unpaired, twotailed Student t test.
We next determined whether radiation modulates co-stimulatory molecule expression, in
vivo. 4T1 or MC38 cells were implanted into syngeneic mice, subcutaneously (s.c.), and allowed
to grow to 300-500 mm3 before local treatment with 8 Gy. 24-48hrs after treatment, tumor tissue
was harvested and formalin fixed. mRNA was isolated from sectioned tumor tissue and mRNA
expression was measured by qRT-PCR. Local irradiation was shown to upregulate the
expression of OX40L in 4T1 and MC38 tumors though neither reached statistical significance
(Fig. 3.2A). In contrast to OX40L, there was no change in 4-1BBL mRNA induced following
radiation treatment in both tumor models (Fig. 3.2B). This data shows that radiation induces
OX40L expression in 4T1 and MC38 tumors but 4-1BBL expression is unchanged.
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Figure 3.2 Effect of radiation on mRNA levels of OX40L and 4-1BBL tumor-bearing mice.
4T1 or MC38 tumor cells were s.c. implanted into syngeneic mice. Tumors 300-500 mm3 in size
received 8 Gy of local radiation under general anesthesia. 48hrs following treatment tumors were
harvested and mRNA was isolated. Bar graph of quantitative RT-qPCR analysis of (A) OX40L
and (B) 4-1BBL expression relative to EiF1 normalized to a single 0 Gy sample. Error bars
represent SD. *P ≤ 0.05.
3.4.2 Reduced number of CD4+Foxp3+ TREGS in 4T1 and MC38 tumor models following
local irradiation does not appear to correlate with the radiation-induced expression of
OX40L and 4-1BBL on tumor cells
Tumor cells are known to recruit TREGS to the tumor microenvironment, as well as induce
CD4+ conventional T cells to a TREG phenotype (Facciabene, Motz, and Coukos 2012; Povoleri
et al. 2013). This recruitment and conversion aids in the maintenance of an immunosuppressive
tumor microenvironment by inhibiting dendritic cell maturation and CTL effector function
(McNally et al. 2011; Bauer et al. 2014; Chen et al. 2017). We previously reported that signals
transmitted by OX40L and 4-1BBL enhanced CTL effector function towards irradiated
colorectal tumor cells (Kumari and Garnett-Benson 2016). In contrast to the positive effect on
CTLs, signals through OX40 and 4-1BB have been shown to abrogate Foxp3 expression in TREG
cells and inhibit their suppressive function (Vu et al. 2007; Kitamura et al. 2009; Smith,
Hoeizinger, and Dominguez 2011; X. Zhang et al. 2018). Thus, we wanted to determine if
radiation-induced expression of OX40L and 4-1BBL on tumor cells decreased TREG frequency in
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vivo. We hypothesized that the higher percentage of OX40L expressing tumor cells, as well as
the greater density of 4-1BBL on tumor cells in the 4T1 murine model as compared to the MC38
model would induce a significant decrease in TREG frequency in the 4T1 model alone. To
investigate this question, 4T1 mammary or MC38 colorectal tumor cells were implanted, s.c.,
into syngeneic mice and allowed to grow to 300-500 mm3 before local treatment with 8 Gy. 2448hrs after treatment, tumor tissue was harvested and flash frozen in O.C.T compound. The
frequency of tumoral CD4+Foxp3+ TREG cells was evaluated by fluorescent IHC (Fig. 3.3). Mice
bearing 4T1 tumors exhibited a significant decrease in the average number of CD4+Foxp3+
TREGS 48h post radiation (avg. 2.155) as compared to untreated mice (avg. 4.129) (Fig. 3.3B).
Radiation did not induce a significant change in CD4+ T cell number (Fig. 3.3C). Similarly,
MC38 tumor bearing mice showed a significant reduction in TREGS following radiation treatment
(avg. 3.2) as compared to control mice (avg. 8.175) (Fig. 3.3E). In addition, the number of CD4+
T cells in MC38 tumor bearing mice was also significantly reduced after treatment with 8 Gy
(Fig. 3.3F).
Interestingly, the degree of TREG reduction appeared greater in MC38 tumors compared to
4T1. We hypothesized that the modulation of OX40L and 4-1BBL on tumor cells could reduce
the frequency of TREG cells within the tumor microenvironment. Though we showed that
radiation modulates the expression of OX40L in both tumor cell lines in vitro (Fig. 3.1), the
frequency of MC38 cells expressing OX40L was relatively low and radiation slightly decreased
the frequency of 4T1 cells expressing OX40L. Additionally, the frequency of 4T1 and MC38
tumor cells expressing 4-1BBL was high, however the density in MC38 tumor cells was low in
comparison to 4T1 MFI (Fig. 3.1D). Despite these differences, exposure of 4T1 and MC38
tumors to radiation resulted in a reduction in TREG cell number. These results indicate that
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radiotherapy reduces TREG cell frequency but differences in tumor expressed OX40L and 41BBL do not appear to facilitate in this reduction.
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Figure 3.3 CD4+Foxp3+ TREGS differentially reduced by radiation in 4T1 and MC38
murine tumors in vivo.
(A) 4T1 tumor cells were subcutaneously implanted into mice. Tumors 300-500 mm3 in size
received 8 Gy of local radiation under general anesthesia. 48hrs following treatment tumors were
harvested and tissue sections co-stained for CD4 and Foxp3 prior to analysis by confocal
microscopy. 10 image fields per mouse were randomly selected and the total number of (B)
CD4+Foxp3+ TREGS and (C) CD4+ T cells were manually counted and the average plotted. (DF) MC38 tumor cells. *P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001 by unpaired, two-tailed Student t
test. Green: CD4; Red: Foxp3; Blue: DAPI.
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3.4.3 CD4+Foxp3+ TREG frequency is still reduced following radiation in the absence of 41BB signaling
To further determine if signaling through 4-1BB can directly affect TREG frequency we
utilized a 4-1BB KO mouse model. MC38 cells were implanted into C57BL/64-1BBnull mice and
tumors were locally irradiated (10 Gy) or untreated. 3 days after treatment the frequency of
tumoral CD4+Foxp3+ TREG cells was evaluated by fluorescent IHC. Radiation treatment showed
a moderate decrease in mean TREG frequency (1.5) as compared to control (2.8) (Fig. 3.4A).
Surprisingly, this decrease was also observed in the CD4+ T cell population (Fig. 3.4B).
Preliminary data evaluating immune cell frequency 6 days post radiation treatment indicated a
rebound in TREG number (data not shown) which may suggest that the decrease observed in the
total CD4+ T cell population is a direct result of the radiation treatment. This reduction was
similar to that observed in WT mice (Fig. 3.3E and 3.3F) suggesting that signaling through 41BB is dispensable and has little effect on tumoral TREG frequency following radiation.
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Figure 3.4 Loss of 4-1BB reduces TREG frequency following radiation.
MC38 cells were implanted into C57BL/641BBnull mice. Mice with tumors 200-300 mm3 in size
received 10 Gy of local radiation under general anesthesia. 3 days following treatment tumors
were harvested and tissue sections stained with CD4 and Foxp3 prior to analysis by confocal
microscopy. 10 image fields per mouse were randomly selected. The total number of (A)
CD4+Foxp3+ TREGS and (B) CD4+ T cells were manually counted and the average plotted. *P ≤
0.05 by unpaired, two-tailed Student t test.

3.4.4 CD8+ TILs increased in irradiated 4T1 but not MC38 tumors
All of the experiments described above examined the effect of radiation-induced
modulation of tumor expressed OX40L and 4-1BBL on TREG frequency. We were unable to
correlate the significant reduction in TREG number observed in both 4T1 and MC38 tumors with
the differential modulation of OX40L and 4-1BBL between these two models. In further
experiments, we expanded our studies to examine radiation-induced differences in the immune
cell profile of 4T1 and MC38 tumor models. We showed that local tumor irradiation
significantly reduces the frequency of tumoral TREG cells in both 4T1 and MC38 models (Fig.
3.3). We next examined the effect of radiation on CD8+ T cells within the tumor
microenvironment as TREG cells are known to inhibit CD8+ CTL activity. In 4T1 tumor-bearing
mice we observed an increase in CD8+ T cell number 48hrs after treatment (avg. 11.65) as
compared to untreated mice (avg. 6.02) though this increase did not reach statistical significance
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(Fig. 3.5A). In contrast, minimal change in CD8+ T cell number was observed in MC38 tumors
24-48hrs following treatment (avg. 1.1 vs 1.26) (Fig. 3.5B). Interestingly, we noted that
untreated 4T1 tumors contained more CD8+ T cells compared to MC38 tumors.
We further assessed changes in the ratio of CD8:TREG cells after treatment with 8 Gy. We
observed a significant increase in the CD8:TREG ratio in irradiated 4T1 tumors (Fig. 3.5C)
whereas the ratio in irradiated MC38 tumors remained unchanged (Fig. 3.5D). Overall, we
concluded that radiation treatment differentially alters CD8+ T cell number based on tumor
model.
A.

B.

4T1

N=7

N=10

C.

MC38

N=4

N=8

N=4
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D.
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N=10

Figure 3.5 CD8+ T cell number increased following radiation treatment in murine tumor
models.
24-48hrs after radiation exposure (8 Gy), tumor tissue sections from (A) 4T1 and (B) MC38
tumor-bearing mice were stained for CD8 and analyzed by confocal microscopy. 10 image fields
per mouse were randomly selected and the total number of CD8+ T cells present in each of 10
randomly selected images were manually counted and the average plotted. CD8:TREG ratio in (C)
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4T1 and (D) MC38 tumor tissue sections. Ratio was calculated by dividing the average number
of CD8 T cells by the average number of TREG cells per mouse. *P ≤ 0.05; ** P ≤ 0.01; *** P ≤
0.001 by unpaired, two-tailed Student t test.
3.4.5 Effect of radiation on RNA immunoprofile
Thus far, our data has shown that local irradiation reduces TREG number in 4T1 and
MC38 tumors, however an increase in CD8+ T cell number was only observed in 4T1 tumors.
These results indicated the differential effect of radiotherapy on different tumor models. 4T1
tumors are widely considered to be poorly immunogenic in contrast to the immunogenic MC38
tumors . To further examine the immune landscape within the tumor microenvironment
following radiotherapy we isolated mRNA from 8 Gy treated and untreated tumors from 4T1 and
MC38 implanted mice. mRNA was analyzed for gene expression using NanoString technology.
Differences in the expression of T cell-associated genes (probes: CD4 and CD8a) showed
increased expression of the CD4 gene after radiation treatment in 4T1 and MC38 tumors (Fig.
3.6A). In contrast, the CD8a gene was increased in irradiated 4T1 cells but no change was
observed in treated MC38 tumors, similar to the cellular composition observed in Fig. 3.5. We
also examined differences in TREGS following radiotherapy (probe: Foxp3). The Foxp3 gene was
reduced in 4T1 tumors while no change was observed in MC38 tumors with radiation.
Additionally, we looked at genes associated with immune cell activation (probes: IFN-g
and Tnfsf4). IFN-g is a pleiotropic cytokine that has been shown to regulate CD8 expansion and
cytotoxicity, as well as induce antitumor effects (Whitmire, Tan, and Whitton 2005; Zaidi 2019).
We found that IFN-g gene expression was induced in irradiated 4T1 tumors but not MC38
tumors. This may likely correlate with the increased number of CD8+ T cells observed in
irradiation 4T1 tumors but not in MC38 tumors (Fig. 3.5). Furthermore, radiation induced a
similar fold change increase in Tnfsf4 (OX40L) in 4T1 and MC38 tumors. This data suggests
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that radiation induces better effector T cell infiltration, immune cell activation and TREG
reduction in 4T1 tumors as compared to MC38 tumors. Further, the observed fold change
increase in Tnfsf4 following radiation indicates that tumor expressed OX40L is likely not the
mechanism of TREG abrogation in either 4T1 or MC38 tumors.
We next analyzed mRNA for gene expression associated with a T cell inflamed tumor
microenvironment as described by Gajewski et al (Gajewski et al. 2017). Both 4T1 and MC38
tumors differentially increased expression of chemokines related to T cell recruitment (probes:
CCL5 and CXCL10) (Fig. 3.6B). Though both chemokine transcripts were increased with
radiotherapy, a greater increase in CCL5 was observed in irradiated MC38 tumors compared to
control while a higher fold change in CXCL10 was seen in irradiated 4T1 tumors. We further
compared 8 Gy treated MC38 and 4T1 tumors for differences in chemokine gene transcripts.
Interestingly, CCL5 and CXCL10 genes were highly expressed in irradiated MC38 tumors as
compared to irradiated 4T1 tumors which may be due to MC38 tumors being more immunogenic
from the onset.
Genes linked to immune inhibitory mechanisms and T cell dysfunction (probes: CD274,
IDO1, and LAG-3) were also analyzed following radiation treatment (Fig. 3.4B). Irradiated
tumors exhibited increased expression of CD274 (PD-L1), IDO1 and LAG-3 genes. Fold change
differences in IDO1 and LAG-3 were similar in both tumor models following radiotherapy. A
greater change in CD274 was seen in MC38 tumors treated with radiation. Finally, we compared
8 Gy treated MC38 and 4T1 tumors for changes in inhibitory genes and noted that irradiated
MC38 tumors expressed more CD274 and LAG-3 gene transcripts as compared to irradiated 4T1
tumors. In contrast, 8 Gy treated 4T1 tumors express higher levels of IDO1 than radiation treated
MC38 tumors. These data indicate that radiation treatment promotes a T cell inflamed tumor
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microenvironment in both 4T1 and MC38 tumors, however the gene profile of irradiated MC38
tumors appears to highly mediate an inhibitory tumor microenvironment in comparison to 4T1
tumors.

Figure 3.6 Immune profiling analysis.
NanoString immune profiling analysis of tumor samples from 0 Gy and 8 Gy treated 4T1 or
MC38 tumor-bearing mice. Fold change in gene expression is listed. (A) Profiling of tumorassociated immune cells and immune activating markers. (B) Profiling of immune genes
expressed in T cell inflamed tumor microenvironment.
3.5

Discussion
We have previously reported on the direct effect radiation treatment has on modulating

TREG phenotype and reducing Foxp3 expression (manuscript submitted). However, the potential
indirect effects of radiation treatment on TREGS within the tumor microenvironment remains
unclear. Our lab, and others, have shown that radiation can modulate the expression of co-
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stimulatory molecules on human tumor cells (Bernstein et al. 2014; Kumari and Garnett-Benson
2016). Further, modulation of tumor expressed OX40L and 4-1BBL enhances CTL effector
function (Kumari and Garnett-Benson 2016). In this study, we assessed the radiation-induced
modulation of OX40L and 4-1BBL co-stimulatory molecules on TREG frequency, as well as
differences in the tumor immune cell profile in two commonly used murine tumor models. First,
we showed that irradiated 4T1 and MC38 tumors differentially modulate the expression of
OX40L and 4-1BBL co-stimulatory molecules. Additionally, we showed that radiation reduces
the number of TREG cells in 4T1 and MC38 tumors, however this reduction does not appear to be
induced by tumor expressed OX40L or 4-1BBL. In addition, we observed an increase in CD8+ T
cell number in irradiated 4T1 tumors but not MC38 tumors which we were unable to correlate
with tumor modulation of OX40L or 4-1BBL. We further analyzed tumors for differences in the
immune cell gene profile and showed that radiation differentially induces a more immunogenic
microenvironment in 4T1 tumors, as well as induces a T cell inflamed tumor microenvironment
in 4T1 and MC38 tumors.
Earlier reports in human tumor cells showed that radiotherapy can induce the expression
of OX40L and 4-1BBL (Bernstein et al. 2014; Kumari and Garnett-Benson 2016). Our results in
murine tumor cells are in line with previously reported data that radiation can modulate the
phenotype of tumor cells by upregulating the expression of OX40L and 4-1BBL. While radiation
did not induce any significant change in the percent of positive expressing cells in both the 4T1
and MC38 models we did observe increases in protein density indicating that the modulatory
effects of radiation is cell line dependent.
OX40 and 4-1BB co-stimulation can reportedly abrogate Foxp3 expression and inhibit
the suppressive function of TREG cells (Kitamura et al. 2009; Smith, Hoeizinger, and Dominguez
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2011; Bulliard et al. 2014; X. Zhang et al. 2018). Co-stimulation in published reports was
achieved with the use of agonist antibodies. We aimed to determine if radiation-induced
expression of OX40L and 4-1BBL on tumor cells can reduce TREG number. We hypothesized
that irradiated 4T1 tumors would induce a more significant decrease in TREG number compared
to the MC38 model as 4T1 cells contain a high percentage of OX40L and 4-1BBL expressing
cells and express moderate to high density of both proteins that is increased with radiation. Our
data showed a significant reduction in TREG frequency following radiation treatment in both 4T1
and MC38 tumor models (Fig. 3.3). Interestingly, we found that radiation had no effect on total
CD4+ T cell frequency in 4T1 tumors but significantly decreased CD4+ T cells in the MC38
model. Though our data showed an increase in OX40L and 4-1BBL protein density in 4T1 and
MC38 tumor cells following radiation treatment we were unable to conclusively correlate protein
modulation with the observed decrease in TREG number. In fact, it is more likely that the
modulation of OX40L and 4-1BBL had no effect on TREG frequency. To further determine
whether 4-1BB signaling can reduce TREG number, we implanted MC38 tumor cells into a 4-1BB
KO mouse model. Similar to results seen in WT mice, we observed a reduction in TREG cell
number and CD4+ T cells 3 days post-treatment (Fig. 3.4). This data further indicates that 4-1BB
signaling had no impact on reduced TREG frequency, in vivo.
Because we were unable to correlate radiation-induced changes in co-stimulatory
molecules with a reduction in TREG cells, we shifted our focus to assess radiation-induced
differences in immune cell composition between our two mouse models. TREGS are known to
exert their suppressive function on several immune cells including CD8+ T cells. As we
observed a significant reduction in TREG number following radiotherapy in both 4T1 and MC38
tumor models we next evaluated tumor samples for changes in CD8+ T cell number. Our data
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showed that radiation increased the frequency of CD8+ T cells, and subsequently the CD8:TREG
ratio, in 4T1 tumors. Surprisingly, we saw no change in CD8+ T cell frequency in MC38 tumors
(Fig. 3.5). We also utilized NanoString technology to analyze the immune cell gene profile in
irradiated tumors (Fig. 3.6A). We analyzed irradiated 4T1 and MC38 for changes in the gene
transcript of CD4 and CD8a compared to untreated tumors. Radiation was found to upregulate
expression of the CD4 gene in both 4T1 and MC38 tumor models. Similar to observed changes
in T cell frequency, CD8a was increased in irradiated 4T1 tumors while gene expression was
unchanged in MC38 tumors. We also looked at radiation induced changes in the immune
activating genes IFN-g and Tnfsf4 (OX40L). Radiation induced expression of IFN-g was
observed 4T1 tumors while MC38 remained relatively unchanged. These data suggest that
radiation may induce a more immunogenic microenvironment in 4T1 tumors as compared to
MC38 tumors.
4T1 tumors are considered to be poorly immunogenic. One factor that could explain this
effect is the BALB/c mouse strain this model is used in. BALB/c mice have been reported to
contain more of the “pro-tumor” M2 macrophages as compared to C57BL/6 mice, used for
MC38 tumors, which skew more towards an M1 phenotype (Mills et al. 2000; Sellers et al.
2012). Furthermore, tumor-associated macrophages primarily consist of M2 macrophages.
Radiation treatment reportedly recruits macrophages to the tumor microenvironment (S. C.
Wang et al. 2013; Jones et al. 2018). Interestingly, low-dose radiation has been shown to
facilitate increased T cell recruitment to the tumor microenvironment by differentiating
macrophages to an M1 phenotype (Klug et al. 2013). Therefore, it may be possible that radiation
treatment alters the balance of M1 to M2 macrophages within the tumor microenvironment. As
the basal amount of M2 macrophages is much higher in BALB/c mice as compared to C57BL/6
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mice the increased amount of M1 macrophages to irradiated 4T1 tumors may promote a more
significant increase in CD8+ T cell infiltration than that seen in MC38 tumors.
We further extended our immune profile analysis to include genes associated with a T
cell inflamed tumor microenvironment as described by Gajewski et al (Gajewski et al. 2017).
4T1 and MC38 tumors both induced expression of T cell recruiting chemokines (CCL5 and
CXCL10) and inhibitory molecules (CD274, IDO1, and LAG-3) (Fig. 3.6B). We then compared
gene expression levels between irradiated MC38 versus irradiated 4T1 tumors. Surprisingly, we
found that the expression of all genes except IDO1 was higher in MC38 tumors, particularly
CCL5 and CXCL10. Irradiated MC38 tumors express markedly greater expression of CCL5 and
CXCL10 mRNA in comparison to 4T1 tumors, however that did not seem to correlate to an
increase in the observed number of CD8+ T cells as assessed by IHC. While we noted an
increase in chemokine associated mRNA we did not analyze tumor tissue for protein expression.
It is possible that secretion of either chemokine was not significantly altered following
radiotherapy which could affect T cell recruitment to the tumor. Therefore, changes in
chemokine secretion could be examined in future studies.
Lastly, we were greatly intrigued by the observed increase in LAG-3 mRNA with
radiation treatment. We previously observed an increase in LAG-3 expressing human iTREG cells
following radiotherapy (manuscript submitted). Our data showed a reduction in tumoral TREG
number post-radiation treatment, however LAG-3 mRNA is shown to be induced. This indicates
that LAG-3 is also being expressed by other cells within the tumor microenvironment. It is
unclear which cell subset is contributing to this increase in expression, however our data
signifies the potential benefit for the use of an anti-LAG-3 blocking antibody. Combination
treatment with anti-PD-1 and anti-LAG-3 blocking antibodies was shown to increase T cell
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proliferation (Lichtenegger et al. 2018). Therefore, radiation and anti-LAG-3 combination
treatment could further enhance the antitumor immune response in both 4T1 and MC38 tumor
models.
In summary, our study provides valuable information on how radiation differentially
modulates tumor phenotype in two commonly used murine models. These results demonstrate
the inhibitory effect of radiation on TREG number, in vivo, and indicates that tumor expressed
OX40L and 4-1BBL does not appear to induce these changes. Furthermore, our study highlights
differences in the immune profile of our two models and that radiation can induce a more
immunogenic tumor microenvironment. These data could be helpful for assessing the effect of
radiation on the immune cell gene profile in murine models and defining the usefulness of
radiotherapy in preclinical studies.
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4

CONCLUSIONS

Radiotherapy remains an important cancer treatment modality, as more than half of
cancer patients receive treatment. The administration of radiation can be curative for some
cancer types when used alone or in combination with other standard treatments such as surgery
or chemotherapy (“Radiation Therapy Basics” n.d.). Unfortunately, treatment for patients with
advanced-stage malignancies is frequently incurable. While the higher doses given for curative
radiotherapy are intended to kill tumor cells through such mechanisms as DNA damage, several
groups have reported on the immune enhancing effect of low dose radiation (Filatenkov et al.
2015; Lugade et al. 2005; Y. Lee et al. 2009; Spary et al. 2014; Gupta et al. 2012).
Low dose radiation has been shown to enhance the anti-tumor immune response through
such avenues as increased infiltration of immune cells to the tumor, dendritic cell activation, and
the modulation of several co-stimulatory molecules on tumor cells (Y. Lee et al. 2009; Gupta et
al. 2012; Bernstein et al. 2014; Garnett et al. 2004; Kumari and Garnett-Benson 2016). While
extensive research has expanded our knowledge on the increased activation and survival of
effector T cells following radiotherapy, it is less clear how radiation effects human CD4+ TREG
cells. Our data in Chapter 2 focused on induced TREGS, similar to those derived within the tumor
microenvironment. We showed that natural and induced TREG cells are more radioresistant as
compared to CD4+ TCONV cells and direct radiation significantly reduced their expression of
Foxp3. Irradiated iTREGS further modulated the expression of signature TREG molecules. A
decrease in CD25 and CTLA-4 expression was seen while LAG-3 and CD73 expression was
upregulated. We observed no change in CD39 and PD-L1 expression. Furthermore, iTREGS
exposed to 10 Gy of radiation were less capable of inhibiting CD8+ T cell proliferation. Based
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on our findings we identified the direct effect of radiation on human induced TREG cell phenotype
and suppressive function.
The effect of radiation treatment on TREG cells has produced conflicting reports. One
reason for such discrepancies could be the differences between natural versus induced TREGS.
Death staining and analysis of Foxp3 expression revealed that natural and induced TREG cells are
similarly affected by radiation treatment. We noted that the rate of Foxp3 expression following
radiotherapy was greater in iTREGS as compared to nTREGS. This difference in Foxp3 reduction
could be due to differences in methylation of the Foxp3 promoter. The Foxp3 promoter in nTREG
cells is fully demethylated in contrast to iTREGS that exhibit partial demethylation. Additionally,
acetylation of the Foxp3 promoter is important for the stability of Foxp3 expression (Kwon et al.
2012). We have previously shown that radiation is capable of epigenetically regulating gene
expression (Kumari et al. 2013). Thus, future studies could investigate epigenetic changes in
natural and induced TREG cells following radiation treatment.
Furthermore, our study focused on iTREGS as these cells are similar to those that would be
induced within the tumor microenvironment. We found that radiation altered the phenotype of
Foxp3+ TREGS. Irradiated cells showed reduced expression of CD25 and CTLA-4, proteins that
are regulated by Foxp3 (Sadlon et al. 2010). Of significant interest was the increased expression
of another Foxp3 regulated gene, LAG-3. LAG-3 is an suppressive molecule that inhibits T cell
proliferation (Okamura et al. 2009). The immunogenic effects of radiation are frequently
discussed however it should be noted that radiation can upregulate the expression of inhibitory
molecules such as PD-L1. It is quite possible that LAG-3 expression is similarly regulated with
radiation. Though irradiated iTREGS induced expression of LAG-3 these cells were still less
suppressive as compared to untreated cells. Currently, anti-LAG-3 blocking antibodies are being
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tested in preclinical studies. Future experiments could investigate whether combination treatment
with radiation and anti-LAG-3 to iTREGS further inhibits their suppressive function.
In Chapter 3, we investigated the role of radiation on tumor cell modulation and its effect
on TREG cells in vivo. In addition, we examined tumors for radiation-induced differences in the
immune cell profile of two commonly used murine tumor models. Previous data from our lab
demonstrated the modulatory effects of radiation on tumor cells (Garnett et al. 2004; Kumari and
Garnett-Benson 2016). Of significance, it was reported that radiation can induce the expression
of the co-stimulatory molecules OX40L and 4-1BBL on colorectal tumor cells. Signals from
these tumor expressed molecules were found to enhance CTL effector activity (Kumari and
Garnett-Benson 2016). Additionally, it has been reported that signaling through OX40 or 4-1BB
can inhibit Foxp3 expression in TREGS and reduce their suppressive function (Kitamura et al.
2009; X. Zhang et al. 2018; Bulliard et al. 2014; Smith, Hoeizinger, and Dominguez 2011). Our
data demonstrates the differential modulation of radiation in 4T1 and MC38 murine tumor
models. We found that radiation differentially modulated the expression of OX40L and 4-1BBL
on 4T1 and MC38 tumor cells. We also revealed that the number of tumoral TREGS was
significantly reduced in 4T1 and MC38 tumors 24-48hrs after exposure to radiation.
Additionally, radiation increased the number of CD8+ T cells in 4T1 tumors, however no change
was observed in MC38 tumors. Finally, we report that the immune profiles of the 4T1 and MC38
tumor models are modulated differently following radiation treatment. Irradiated 4T1 tumors
appear to be more immunogenic as compared to MC38 tumors. Lastly, radiation was shown to
increase the expression of genes associated with a T cell inflamed tumor microenvironment in
both 4T1 and MC38 tumors though expression was higher in MC38. Overall, these data indicate
that local tumor irradiation can significantly affect the tumor immune profile, however these
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changes were highly variable between two commonly utilized murine tumor models. Moreover,
we can report that tumor expressed OX40L and 4-1BBL does not appear to mitigate TREG
reduction or enhance the presence of CD8+ T cells following radiation treatment.
The study presented in Chapter 3 is the first to evaluate the effect of tumor expressed
OX40L and 4-1BBL on TREG cells. Several studies have reported the inhibitory effect of OX40
or 4-1BB co-stimulation on Foxp3 expression and TREG suppressive function in murine models,
however many of these studies utilized agonist antibodies. We attempted to induce expression of
OX40L and 4-1BBL on murine tumor cells using radiotherapy. In line with results observed in
human tumor cells, 4T1 and MC38 murine tumor cell lines differentially modulated the
expression of OX40L and 4-1BBL. While radiation increased the density of OX40L in both cell
lines, 4T1 cells contained a higher frequency of positive cells as compared to MC38 cells.
Additionally, radiation slightly decreased the frequency of OX40L positive 4T1 cells while the
frequency of MC38 cells remained unchanged. In contrast, both cell lines expressed a high
frequency of 4-BBL expressing cells but the density of 4-1BBL was markedly higher in 4T1
cells compared to MC38 cells. We also examined the expression of OX40L and 4-1BBL in vivo.
mRNA from tumor samples revealed that local tumor irradiation induced OX40L in both 4T1
and MC38 tumors but 4-1BBL expression was unaltered in both. While we observed a
significant decrease in TREG cells from 4T1 and MC38 tumors our data did not substantiate an
obvious link between induced OX40L and 4-1BBL expression and TREG reduction. Though we
were able to perform preliminary experiments on MC38 tumor cells in 4-1BB KO mice,
additional experiments to evaluate 4-1BBL expression and its effect on TREGS was difficult. The
use of Nanostring technology allowed us to evaluate the gene profile of immune cells with the
tumors from both models, however a probe for 4-1BBL was not available. Additionally, we were
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unable to obtain 4-1BB KO mice on a BALB/c background within our experimental timeframe.
To directly study the tumor induced effect of OX40L and 4-1BBL, future experiments could
evaluate the frequency and suppressive function of TREG cells co-cultured with OX40L or 41BBL over-expressing tumor cells, in vitro, or examine TREGS isolated from 4T1 tumors in OX40
KO or 4-1BB KO mice.
We further compared differences in the immune cell gene profile following radiation
treatment using NanoString technology to examine if there were any obvious disparities (1)
induced by radiation within each tumor model and (2) between the tumor models that could
account for differences in TREG and CD8+ T cell frequency. We found that radiation induced the
gene transcript of CD4 and CD8a in 4T1 tumors while only CD4 was increased in MC38. This
data correlates with the increase in CD8+ T cell number observed in irradiated 4T1 tumors but
not MC38 (Fig. 3.5). Radiation was further shown to greatly decrease the gene transcript of
Foxp3 in 4T1 which correlated with the significant decrease in CD4+Foxp3+ TREG cell number
(Fig. 3.3). Surprisingly, the Foxp3 gene transcript was unaltered with radiation in MC38 tumors
despite seeing a significant decrease in tumor TREG number. It is not immediately clear why
changes in the Foxp3 gene transcript did not coincide with the observed decreased in tumor TREG
number. Experimental repeats would be needed to investigate this further. We also looked at two
immune activating genes, IFN-g and Tnfsf4 (OX40L). Only irradiated 4T1 tumors increased
expression of the IFN-g gene while only a minimal increase was seen in MC38 tumors.
Interestingly, both tumor models increased expression of the OX40L gene transcript. This
correlated with the increase observed in OX40L mRNA isolated from in vivo murine tissue. This
data indicates that irradiated 4T1 tumors are more immunogenic as compared to MC38 tumors.
Additionally, this data, in concert with the increase in OX40L mRNA, suggests that radiation
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induced expression of OX40L on tumor cells does not appear to correlate with our observed
decrease in TREG cells in both tumor models or the increased expression of CD8+ T cells in 4T1
tumors.
Currently, clinical ICB treatment is only approved for use as a monotherapy. For those
patients that do respond well, ICB treatment has been shown to increase patient survival (Hodi et
al. 2010; Topalian et al. 2019). Unfortunately, most eligible patients do not respond to treatment
signifying a major hurdle for scientists and clinicians. Combination treatment with radiation is
currently being tested in clinical trials to help address this problem. Several preclinical studies
have reported significantly delayed tumor growth and enhanced antitumor responses with
combination therapy compared to ICB treatment alone demonstrating a promising role for
radiation in combination with ICB (Dewan et al. 2009; Deng et al. 2014; Sharabi et al. 2015; K.
J. Kim et al. 2017). In addition, combined ICB and radiation treatment has been shown to induce
an abscopal effect in murine tumor models (Dewan et al. 2009; Rodriguez-Ruiz et al. 2016). An
abscopal response has also been observed in human patients, however this effect is rare (Hiniker
et al. 2012; Golden et al. 2013; Grimaldi et al. 2014). Though the mechanism inducing this
phenomenon is not known, however it is understood that a competent immune system is required
to obtain a response. Therefore, it is possible that the enhanced antitumor response induced by
radiation is able to enhance CTL activity while simultaneously inhibiting TREG function.
Despite the significant success of CTLA-4 and PD-1/PD-L1 checkpoint inhibitors in
cancer treatment its use is ineffective in most eligible patients, while some that initially
responded well to treatment later acquire resistance (Pitt et al. 2016; Koyama et al. 2016). Thus
the development of new combination treatment regimens, as well as new therapies targeting
alternative inhibitory receptors, is currently being conducted. The use of immunocompetent
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preclinical murine tumor models supports the development of cancer therapeutics by allowing
for the study of interactions between tumor and immune cells. However, differences in the
immune cell composition of various murine models can have a significant effect on therapeutic
results. Additionally, the effect of common cancer treatment modalities, such as radiation and
chemotherapy, can differentially alter the immune landscape of murine tumor models. 4T1
(poorly immunogenic) and MC38 (highly immunogenic) are two commonly used murine tumor
models that exhibit different responses to radiation treatment. Our mRNA results indicate that
radiotherapy can induce a more immunogenic tumor microenvironment in the 4T1 tumor model,
as well as enhance the expression of genes associated with a T cell inflamed microenvironment
in both models, particularly MC38.
Overall, our study demonstrates the inhibitory effects of radiation on TREG cells. We also
show that the radiation-induced modulation of the co-stimulatory molecules OX40L and 4-1BBL
had no effect on observed changes in immune cell frequency. Interestingly, we found that
radiation differentially modulates the immune cell gene profile 4T1 and MC38 tumors. These
murine models are commonly used for preclinical immunotherapeutic studies in combination
with radiotherapy. Therefore, these data will be helpful for assessing the usefulness of radiation
treatment in preclinical cancer immunotherapy studies and how the immune cell gene profile in
murine models may affect these studies.
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